Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$477.70 USD

477.70
1,019,700

+5.79 (1.23%)

Updated Oct 25, 2024 03:59 PM ET

After-Market: $477.88 +0.18 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc.

by Zacks Equity Research

Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc. are included in this blog.

Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings?

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis

by Zacks Equity Research

AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.

Will Lower Aggregate Revenues Hurt Intel's (INTC) Q4 Earnings?

by Zacks Equity Research

Intel's (INTC) performance in fourth-quarter 2021 is likely to reflect headwinds in the enterprise business of the data center segment.

Silicon Motion (SIMO) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Silicon Motion's (SIMO) performance in the fourth quarter of 2021 is likely to have benefited from increased sales of SSD and eMMC and UFS controllers.

PTC Gearing Up for Q1 Earnings: What is in the Offing?

by Zacks Equity Research

PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.23%: What You Should Know

by Zacks Equity Research

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $228.08, marking a -0.23% move from the previous day.

Will Higher Revenues Drive Corning's (GLW) Q4 Earnings?

by Zacks Equity Research

Corning's (GLW) performance in the fourth quarter of 2021 is likely to have been primarily driven by growth in the Optical Communications business.

Nalak Das headshot

6 Must-Buy Large-Cap Stocks Ahead of Q4 Earnings Next Week

by Nalak Das

Six large-cap companies will report earnings next week. These are: TSLA, URI, FCX, VRTX, STLD and BRO.

Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sumit Singh headshot

4 Stocks With Impressive Interest Coverage Ratio to Invest In

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGCO) and Vertex (VRTX) are sound enough to meet financial obligations.

4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

by Zacks Equity Research

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.

Will Lower Aggregate Revenues Hurt Verizon's (VZ) Q4 Earnings?

by Zacks Equity Research

Verizon's (VZ) performance in the fourth quarter of 2021 is expected to have been affected by the sale of the Verizon Media unit.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.1%: What You Should Know

by Zacks Equity Research

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $230.84, marking a -0.1% move from the previous day.

Kinjel Shah headshot

Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks

by Kinjel Shah

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

The Zacks Analyst Blog Highlights: Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc

by Zacks Equity Research

Bank of America Corp., Broadcom Inc., Royal Dutch Shell plc, Automatic Data Processing, Inc. and Vertex Pharmaceuticals Inc are highlighted in this Analyst Blog article.

Mark Vickery headshot

Top Analyst Reports for Bank of America, Broadcom & Royal Dutch Shell

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Broadcom Inc. (AVGO), and Royal Dutch Shell plc (RDS.A).

Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?

by Zacks Equity Research

Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.

Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children

by Zacks Equity Research

The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.

Is Vertex (VRTX) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed at $223.96 in the latest trading session, marking a +0.95% move from the prior day.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed at $221.86 in the latest trading session, marking a -0.3% move from the prior day.

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed at $223.32 in the latest trading session, marking a +0.63% move from the prior day.